Goldenwell Biotech Inc
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech Inc (GWLL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.684x
Based on the latest financial reports, Goldenwell Biotech Inc (GWLL) has a cash flow conversion efficiency ratio of -0.684x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($59.38K) by net assets ($-86.84K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Goldenwell Biotech Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Goldenwell Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Goldenwell Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Goldenwell Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mobio Technologies Inc
V:MBO
|
0.101x |
|
Netlinkz Ltd
AU:NET
|
0.084x |
|
ASM INT (AVS.SG)
STU:AVS
|
0.086x |
|
Phio Pharmaceuticals Corp
NASDAQ:PHIO
|
-0.212x |
|
Electroprecizia SA
RO:ELZY
|
N/A |
|
QNB Finans Finansal Kiralama AS
IS:QNBFL
|
0.104x |
|
Intermedical Care and Lab Hospital Public Company Limited
BK:IMH
|
0.016x |
|
Castec Korea Co Ltd
KQ:071850
|
0.182x |
Annual Cash Flow Conversion Efficiency for Goldenwell Biotech Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Goldenwell Biotech Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-47.24K | $-123.08K | 2.605x | +292.46% |
| 2023-12-31 | $84.72K | $-114.69K | -1.354x | +74.55% |
| 2022-12-31 | $201.62K | $-1.07 Million | -5.320x | -682.42% |
| 2021-12-31 | $301.71K | $-205.14K | -0.680x | -2572.43% |
| 2020-12-31 | $248.57K | $-6.32K | -0.025x | -- |